Vincentage Pharma Co., Ltd
Clinical trials sponsored by Vincentage Pharma Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to tackle high blood pressure and weight together Results expected Oct 2026 (estimated)
-
New Weight-Loss pill VCT220 enters final testing phase
Disease control CompletedThis phase 3 trial tests whether VCT220, a daily pill that targets GLP-1 receptors, can help overweight or obese adults lose weight. About 840 participants will take either a high dose, low dose, or placebo for 12 months. The main goals are to see how much weight they lose and ho…
Phase 3 • Sponsor: Vincentage Pharma Co., Ltd • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Obesity drug VCT220 put to the test: will common meds interfere?
Knowledge-focused CompletedThis study looked at how two common drugs—rifampin and itraconazole—change the way the body processes VCT220, a new medicine being developed for obesity. Thirty-two healthy adults took VCT220 alone and then with each of these drugs to see if their levels in the blood changed. The…
Phase 1 • Sponsor: Vincentage Pharma Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New obesity drug VCT220 put through drug interaction tests
Knowledge-focused CompletedThis study checked how a new experimental drug for obesity, VCT220, interacts with three common medications (repaglinide for diabetes, rosuvastatin for cholesterol, and digoxin for heart conditions). Twenty-four healthy overweight adults took VCT220 alone and then with the other …
Phase 1 • Sponsor: Vincentage Pharma Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Kidney function may change how obesity drug works
Knowledge-focused CompletedThis study looked at how a single dose of the drug VCT220 behaves in people with moderate kidney problems compared to those with healthy kidneys. Researchers measured drug levels in the blood and checked for side effects. The goal is to find the right dose for people with kidney …
Phase 1 • Sponsor: Vincentage Pharma Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC